{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:27Z","timestamp":1791489627584,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":243,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101421","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:08:29Z","timestamp":1789376909000},"page":"101421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment patterns and clinical outcomes among patients with metastatic castration-resistant prostate cancer: a multinational retrospective medical record review"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2904-6980","authenticated-orcid":false,"given":"Robert J.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Niyazov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Nazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie Derrien","family":"Ansquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareedat","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kirker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Schlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctarc.2026.101421_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101421_bib0002","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/0284186X.2019.1662084","article-title":"Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study","volume":"59","author":"Westerberg","year":"2020","journal-title":"Acta Oncol."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101421_bib0003","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1002\/cncr.31384","article-title":"Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-a population-based analysis of 2 national cohorts","volume":"124","author":"Helgstrand","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2026.101421_bib0004","first-page":"1","article-title":"Metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: treatment patterns from the PROXIMA Prospective Registry","volume":"4","author":"Akaza","year":"2018","journal-title":"J. Glob. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101421_bib0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/CEJ.0000000000000981","article-title":"Cancer mortality in Europe in 2020, and an overview of trends since 1990","volume":"35","author":"Santucci","year":"2026","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.ctarc.2026.101421_bib0006","doi-asserted-by":"crossref","unstructured":"Francini E, Gray KP, Shaw GK, Evan CP, Hamid AA, Perry CE, et al. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate cancer Prostatic Dis. 2019;22(3):420\u2013427. doi:10.1038\/s41391-018-0121-2.","DOI":"10.1038\/s41391-018-0121-2"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101421_bib0007","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41391-021-00344-1","article-title":"The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population","volume":"24","author":"Westgeest","year":"2021","journal-title":"Prostate Cancer Prostatic. Dis."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101421_bib0008","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s11523-021-00837-y","article-title":"Exploring the impact of treatment switching on overall survival from the PROfound study in homologous recombination repair (HRR)-mutated metastatic castration-resistant prostate cancer (mCRPC)","volume":"16","author":"Evans","year":"2021","journal-title":"Target. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101421_bib0009","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/s12094-019-02274-w","article-title":"Age, gleason score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor group (Uro-oncological tumors) of the spanish society of radiation oncology (SEOR)","volume":"22","author":"Valero","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ctarc.2026.101421_bib0010","doi-asserted-by":"crossref","unstructured":"Ng K, Wilson P, Mutsvangwa K, Hounsome L, Shamash J. Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England. Prostate cancer Prostatic Dis. 2021;24(3):718\u2013724. doi:10.1038\/s41391-020-00316-x.","DOI":"10.1038\/s41391-020-00316-x"},{"issue":"22","key":"10.1016\/j.ctarc.2026.101421_bib0011","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101421_bib0012","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/21681805.2021.1936626","article-title":"Real world treatment utilization patterns in patients with castration-resistant prostate cancer","volume":"55","author":"Vigneswaran","year":"2021","journal-title":"Scand. J. Urol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101421_bib0013","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol."},{"issue":"Suppl 4","key":"10.1016\/j.ctarc.2026.101421_bib0014","article-title":"662P Genomic\/genetic testing (GT) patterns for patients with metastatic castrate-resistant prostate cancer (mCRPC): interim results from a real-world study in Europe (EU5)","volume":"31","author":"Leith","year":"2020","journal-title":"Ann. Oncol."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101421_bib0015","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101421_bib0016","author":"Chi","year":"2022","journal-title":"Present. ASCO Annu. Meet."},{"key":"10.1016\/j.ctarc.2026.101421_bib0017","article-title":"Real world (rw) racial differences in treatment (tx) patterns and clinical outcomes among patients (pts) with mCRPC","author":"Barata","year":"2023","journal-title":"Present. ASCO Annu. Meet."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101421_bib0018","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1007\/s12325-022-02073-w","article-title":"Real-world treatment patterns in metastatic castration-resistant prostate cancer across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan","volume":"39","author":"Leith","year":"2022","journal-title":"Adv. Ther."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101421_bib0019","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101421_bib0020","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101421_bib0021","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12885-019-5280-6","article-title":"Abiraterone acetate plus prednisone for the management of metastatic castration-resistant prostate cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study","volume":"19","author":"Boegemann","year":"2019","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.ctarc.2026.101421_bib0022","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.euros.2022.08.018","article-title":"Real-world treatment sequencing in patients with metastatic castration-resistant prostate cancer: results from the prospective, international, observational prostate cancer registry","volume":"45","author":"Bjartell","year":"2022","journal-title":"Eur. Urol. Open. Sci."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101421_bib0023","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/bco2.116","article-title":"Mortality in men with castration-resistant prostate cancer: a long-term follow-up of a population-based real-world cohort","volume":"3","author":"Khoshkar","year":"2022","journal-title":"BJUI. Compass."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422600331X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422600331X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:41:11Z","timestamp":1791488471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422600331X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":23,"alternative-id":["S246829422600331X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101421","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns and clinical outcomes among patients with metastatic castration-resistant prostate cancer: a multinational retrospective medical record review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101421","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101421"}}